Seqens commits to US market with multi-million dollar investment in R&D
A redeveloped R&D facility will enhance Seqens' capabilities in developing and producing APIs and active delivery systems development
Just 3 months after Seqens was merged with Wavelength Pharmaceuticals to create a significantly larger and diversified CDMO the company has made a bold move to increase its US presence with a multimillion-dollar investment in new R&D facilities at its laboratory in Devens, Massachusetts.
The investment will enable the specialist manufacturer of APIs and pharmaceutical intermediates to increase its R&D capability and productivity of APIs and active delivery systems (lipids and polymers) development which, in turn, will bolster its global R&D network.
Furthermore, the transaction is set to strengthen the company’s US foothold — which also includes a sales office and CDMO operation in nearby Newburyport — and demonstrates the company's commitment to broadening its reach in the US market.
In addition to the re-development of its Devens laboratory, Seqens is investing significantly across the enterprise in its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, HPAPIs and biocatalysts.
Seqens' President Pierre Luzeau said the combination of Wavelength's technologies, products and expertise will enable the company to "accelerate the projects launched in recent months" and support customers worldwide in the development of their projects.
The merger with Wavelength broadens Seqens' global reach by providing production facilities in Israel and India, and sales offices in Europe and the US.
The expansion projection is expected to be completed by the beginning of 2023.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance